Objectives: During HIV-1 infection, the development, phenotype, and functionality of B cells are impaired. Transitional B cells and aberrant B-cell populations arise in blood, whereas a declined percentage of resting memory B cells is detected. Our study aimed at pinpointing the demographic, immunological, and viral factors driving these pathological findings, and the role of antiretroviral therapy in reverting these alterations.
Introduction
During chronic HIV-1 infection, functional perturbations of B cells take place including hypergammaglobulinemia [1] , polyclonal activation [2] , and poor immune responses against pathogens and vaccination antigens [3] . These abnormalities may be the consequences of alterations in the physiological development of B cells, which normally migrate from the bone marrow into the periphery, convert first into transitional and then mature into naive B cells. Upon antigen encounter, naive B cells differentiate into plasma cells and produce specific antibodies. When infection is cleared, most activated B cells undergo apoptosis, except for some cells constituting the resting memory B-cell pool, which is essential for a rapid secondary immune response.
In the chronic phase of the natural course of HIV-1 infection, the B-cell subsets are altered including resting memory B cells, which are severely depleted and transitional B cells, which are expanded [4] . In addition, aberrant B-cell populations, including activated memory and tissue-like memory (TLM) B cells, which are present at very low levels in HIV-1-negative individuals [5] , rise in the blood of HIV-1-infected individuals. These aberrant cells are characterized by the low expression of the surface maker CD21 and display features of immune activation [6] and cellular exhaustion [5] . The factors driving the pathological alterations of B-cell subsets are poorly characterized. Antiretroviral therapy (ART) has only a limited effect on the normalization of the B-cell compartment. Resting memory B cells are maintained if ART is initiated soon after primary infection as shown in both HIV-1-infected children and adults [7] . However, it remains to be elucidated whether ART can ever lead to replenishment of resting memory B cells.
In order to pintpoint the factors involved in pathological changes of B cells, we investigated whether the different B-cell subpopulations are affected by demographic, immunological, and viral factors in HIV-1-infected individuals. We studied patients with different disease progression, including naive to therapy (NAIVE), elite controllers, and ART-treated patients with and without viral control (ART and ART-FAIL, respectively). Furthermore, to fully understand the impact of ART on the B-cell compartment, we prospectively evaluated the ART-FAIL group after switching to a highly successful therapeutic regimen.
Methods

Study participants and blood collection
This is a cross-sectional study including a total of 216 individuals grouped as follows: 144 were HIV-1-infected individuals of whom 47 were NAIVE with plasma viral load above 75 copies/ml, 18 were elite controllers not eligible for therapy and with at least three plasma HIV-1 RNA determination below 75 copies/ml spanning the 12 months before the blood collection [8] , 49 received ART controlling the plasma viral load under detectable levels (ART), and 30 were patients with persistent HIV-RNA load more than 75 copies/ml despite treatment (ART-FAIL). Seventy-two HIV-1-negative volunteers reporting no diseases and general good healthy conditions were included as healthy controls. Participants' characteristics, which include age, sex, HIV-1 risk factor, hepatitis B and C virus (HBV and HCV, respectively) coinfection, viral load, CD4 þ T-cell counts, and nadir of CD4 þ T cells are reported in Table 1 . Pairwise comparisons of patients' characteristics are reported in the Table Supplemental digital content 1, http://links. lww.com/QAD/A307. In order to evaluate the relevance of viremia and therapy on causing and ameliorating B-cell dysfunctions, individuals were also stratified in treated (including ART and ART-FAIL individuals) and untreated (including elite controllers and NAIVE) or according to the plasma viral load more than 75 copies/ml (including NAIVE and ART-FAIL patients) and less than 75 copies/ml (including elite controllers and ART patients) for multivariable analysis. Furthermore, patients included in the ART-FAIL group were prospectively followed for 144 weeks after switching their failing regimen to a different and successful therapeutic regimen of drugs including raltegravir, etravirine and maraviroc or darunavir [8] .
The institution's ethical committees approved the study and all study participants gave a written informed consent. Patient's whole blood was collected at the Stockholm South General Hospital (Sweden), at the San Raffaele Scientific Institute of Milan (Italy), and at the Ospedale Sacco of Milan (Italy). Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll Gradient centrifugation (Lympholite; Cedarlane, Burlington, North Carolina, USA), frozen, and stored in liquid nitrogen until experiments were performed.
B-cell phenotype
Multicolor flow cytometry was performed on PBMCs by acquiring 10 6 formaldehyde-fixed cells at the LSRII (Becton Dickinson, Franklin Lakes, New Jersey, USA) or FACS Gallios (Beckman Coulter, Brea, California, USA) flow cytometers. The following mouse antihuman fluorochrome-conjugated monoclonal antibodies (BD) were used: CD19 PERCP-Cy5.5 (clone SJ25C1), CD27 V450 (clone M-T271), CD21 PE (clone B-ly4), and CD10 PE-Cy7 (clone HI101). Dead cells were excluded using the Live/Death Vivid detection kit labeled with a near-infrared dye (Invitrogen, Carlsbad, California, USA). The following gating strategy was used (see and live B cells were gated on Vivid-CD19 þ lymphocytes. Transitional B cells were identified as CD19 þ CD27 À CD10 þ . Thereafter, the CD10 À cell population was gated and naive (CD27 À CD21 highþ ), resting memory (CD27 þ CD21 highþ ), activated memory (CD27 þ CD21 À ), and TLM (CD27 À CD21 À ) B cells were identified. Analyses were performed using FlowJo software version 8.8.3 (Tree Star Inc., Ashland, Oregon, USA). 
Statistical analyses
Results
Distribution of B-cell subsets in HIV-1-infected patients and uninfected controls
In order to verify whether the percentages of B-cell subpopulation were altered among HIV-1-infected individuals and in comparison with healthy controls, the percentages of transitional, naive, resting memory, activated memory, and TLM B cells were evaluated ( groups of HIV-1-infected individuals or in comparison with healthy controls were reported ( Fig. 1) . Specifically, compared to healthy controls, the transitional B cells were significantly expanded in the NAIVE group, the naive B cells in the ART, and the activated memory and TLM B cells in NAIVE and ART-FAIL patients. In ART and ART-FAIL individuals, resting memory B cells were significantly reduced.
B-cell subpopulation distributions in the elite controller group were surprisingly also altered ( Fig. 1 ). They presented with significantly lower percentages of naive and higher percentages of activated memory B cells compared to healthy controls. Elite controllers maintained normal levels of transitional, resting memory, and TLM B cells. Interestingly, they also showed significantly higher levels of resting memory B cells compared to NAIVE as well as ART and ART-FAIL patients.
Role of demographic and HIV-1-related factors in the B-cell subset distribution of HIV-1-infected patients
In order to investigate factors associated with alteration of B-cell subpopulations, demographic, immunological, and viral characteristics as well as ART exposure were evaluated at multivariable analysis. Viremia was significantly associated with alterations of most B-cell subpopulations ( Table 2) . Indeed, patients with viral load more than 75 copies/ml had higher frequencies of activated memory and TLM and lower naive B cells. The untreated patients were characterized only by higher values of transitional B cells compared to the treated ones. Furthermore, the multivariable analysis evidenced that higher values of resting memory and activated memory B cells and lower naive B cells were associated with higher values of nadir CD4 þ T cells. No alterations were observed in association with absolute CD4 þ T-cell counts. In addition, HCV coinfection as compared to individuals with no other coinfection, was associated with higher percentages of transitional and naive B cells, and lower activated memory B cells ( Table 2) .
Differences in specific B-cell populations were also observed according to HIV-1 risk factor and sex: specifically, homosexual behavior correlated with lower percentages of activated memory; and women showed lower frequencies of resting memory B cells than men. Age did not correlate with any of the B-cell subpopulations.
Control of viral load and the recovery of CD4 R T cells lead to normalization of all B-cell subpopulations except resting memory B cells
As our results showed a strong association between viral load and the B-cell subset alterations, we evaluated the effects of a protracted and successful antiretroviral regimen on the B-cell compartment in chronic, multidrug-experienced individuals, that is, the ART-FAIL group. After 24 weeks from the start of the new therapeutic regimen, viral load dropped below 75 copies/ ml in all patients (data not shown). CD4 þ T-cell counts rose from a median count of 209 (interquartile range: 83.0-305.0) cells/ml at baseline to 425 (interquartile range: 294.0-609.0; P < 0.0001) cells/ml at 24 weeks to finally reach at 144 weeks 497.5 (interquartile range: 333.0-575.0; P < 0.0001 between baseline and 144 weeks; P ¼ NS between t ¼ 24 weeks and t ¼ 144 weeks) cells/ml (data not shown). As shown in Fig. 2 , transitional, naive, activated memory, and TLM B-cell distributions returned to normal levels already after 24 weeks of treatment, and the same trend continued thereafter. At 144 weeks, the transitional, activated memory, and TLM were significantly lower than those in healthy controls (P < 0.0001) and naive B cells were significantly higher than those in healthy controls (P < 0.0001). In contrast to what noticed with the other subsets, the percentage of resting memory B cells did not increase and remained below normal levels during the entire follow-up period (P < 0.0001). A specific analysis excluded an impact of sex on the resting memory B-cell distribution during ART (data not shown).
In order to further investigate the factors driving the persistence of low percentages of resting memory B cells, we evaluated whether the frequency of resting memory B cells was linearly associated with viral load and CD4 þ Tcell counts at all the three time-points of follow-up (i.e., baseline, week 24, and week 144). No correlation was observed between resting memory B cells and viral load at any of the investigated time-points (data not shown). Interestingly, baseline resting memory B cells were associated with higher CD4 þ T-cell counts at baseline or at 24 weeks (r ¼ 0.54, P ¼ 0.002 and r ¼ 0.51, P ¼ 0.004, respectively), but the correlation was lost in relation to the 144-weeks CD4 þ T-cell values (r ¼ 0.23, P ¼ 0.23). In addition, resting memory B cells at 24 or 144 weeks did not correlate with CD4 þ T-cell counts at any of the investigated time-point (data not shown).
Discussion
During the natural course of HIV-1 infection, profound alterations of the B-cell compartment occur characterized by hyperactivation of B cells and consequent hypergammaglobulinemia [1] , increase of cell turnover [9] , plasmablast differentiation [6] , autoantibody production [10] , and appearance of cell subpopulations, which are usually not present in uninfected individuals [6] . Introduction of ART was shown to revert most of these alterations [2, 11, 12] , thus suggesting that viremia was the driving force for these impairments. However, whether viremia directly impacts on the B-cell alterations independently of other factors has not been previously evaluated. Here we demonstrate for the first time in a multivariable analysis that plasma HIV-1 RNA load, independently of other variables, has a direct impact on specific B-cell subpopulations. In fact, in patients with viremia more than 75 copies/ml, an increase in the percentage of activated memory and TLM B cells and a decrease in the percentage of naive B cells were shown.
We did not find an association between the CD4 þ T-cell count and the frequency of any B-cell population, which is in line with previous data from Malaspina et al. [13] . These authors also observed that, during HIV-1 infection, a decrease in CD4 þ T-cell counts was associated with an increase in IL-7 production, which in turn directly correlated with viremia and transitional B-cell increase. In our multivariate analysis, a low number of nadir CD4 þ T cells showed a strong correlation with low levels of resting memory and activated memory and high levels of naive B cells. This suggests that loss of CD4 þ T cells, despite subsequent recovery of the CD4 þ T-cell number, can heavily impact on the physiological maintenance of the B-cell compartment.
Our study demonstrated for the first time that HCV coinfection is an independent factor for B-cell subset alteration, showing a direct correlation with transitional and naive B cells and an inverse correlation with activated memory B cells. These results indicate that in the same individual, HIV-1 and HCV may synergize to induce similar B-cell alterations. Whether HCV shares analogous mechanisms of action with HIV-1 to affect the B-cell compartment needs still to be investigated. In contrast to our results, Sugalski et al. [14] recently demonstrated that activated memory besides transitional B cells are increased during chronic HCV infection. This suggests that HCV alone, or in combination with HIV-1, may induce different effects on B-cell subpopulations. Sugalski et al. [14] further showed that serum IL-7 levels or CD4 þ T-cell frequency did not correlate with transitional or activated memory B cells percentages during chronic HCV infection, as instead reported during HIV-1 infection [13] , thus suggesting that other factors may be involved in alterations of the B-cell subsets. Interestingly, production of the B-cell activating factor (Blys/BAFF) was shown to correlate with similar alteration of B cells in HCV, HIV-1, and HIV-2 infection [14] [15] [16] [17] . Blys/BAFF may, thus, be a common factor driving abnormal activation of B-cell populations during these viral infections.
A goal in the treatment of HIV-1 infection is the recovery of the severely depleted pool of memory B cells taking place during chronic HIV-1 infection [18, 19] , in order to restore impaired serological memory against HIV-1 and other secondary antigens [3, 20, 21] . Here we show that the percentages of resting memory B cells from chronically infected patients with multiple failures to ART regimens do not rise despite successful ART for as long as 144 weeks. In previous studies, the increase of memory B cells in chronically HIV-1-infected individuals following ART for various time length was usually slow and incomplete [4, 22, 23] . A recent study by Moir et al. [24] , however, showed that resting memory B cells increased significantly after 1 year of ART suggesting that the recovery of resting memory B cells may be achievable. In the study, Moir et al. [24] also demonstrated that patients initiating ART within 6 months from infection showed the higher levels of resting memory B-cells as compared to chronically infected individuals. These data support our previous finding that only early initiation of ART applied within the first phases of infection is associated with preservation of the resting memory B cells in HIV-1-infected children and adults [7, 25] . As resting memory B cells are responsible for mounting rapid secondary immune responses, their depletion has an important consequence on the quality of humoral immunity of the patients, with implications for routine vaccination protocols and for the study design of HIV-1 vaccines.
At 144 weeks of therapy, the frequency of the transitional, activated memory, and TLM B-cell subpopulations was significantly reduced in HIV-1-infected patients as compared to healthy controls. This is an interesting finding which deserves further investigation. As the number of naive B cells also increased significantly in the patients treated with antiretrovirals in relation to healthy controls, the lower frequency of transitional, activated memory, and TLM B cells may only reflect distribution dynamics within the B-cell compartment in the treated patients. As an alternative explanation, it should be considered that activated memory and TLM B cells are activated cells with a pro-apoptotic phenotype [26] and may progressively be depleted over time during antiretroviral therapy.
In this study, we evaluated B-cell subpopulations in a consistent number of elite controllers. Interestingly, resting memory B cells in this group were maintained at levels comparable to what found in healthy controls, strengthening the relevance of a preserved T-cell compartment to avoid depletion of resting memory B cells during HIV-1 infection. Surprisingly, the percentages of activated memory B cells in elite controllers were altered, comparable to the increased levels found in NAIVE and ART-FAIL individuals. Whether this is a consequence of low levels of viral replication ongoing at tissue levels or of a generalized immune activation has to be clarified.
Conclusion
In conclusion, our study clearly showed that HIV-1 viremia and nadir CD4 þ T cells are major and independent determinants together with HCV coinfection in driving the impairment of the B-cell compartment. ART given during chronic HIV-1 infection leads to normalization of all the B-cell subsets with the exception of resting memory B cells. These observations have important clinical consequences as resting memory B cells are responsible for longlasting memory against pathogens encountered during life and vaccine antigens [27] . Preserving the ability to form and maintain resting memory B cells in HIV-1 individuals by early treatment would ensure a better response to pathogens and vaccines.
